This interview discusses how BCMA-directed CAR T-cell therapy in multiple myeloma may be more effective when administered ...

Wang also acknowledges emerging platforms such as CAR NK cells and in vivo CAR T technologies but notes these remain ...

Liu described the CAR-like T cells as cytokine-activated lymphocytes engineered with the tumor-targeting and -penetrating ...

Chimeric antigen receptor (CAR) T cell-based therapy has greatly improved cancer treatment, especially for hematologic cancers. 1 By providing T cells with synthetic receptors that target tumor ...

Nona Biosciences ("Nona"), a global biotechnology company advancing biologics discovery through innovative technology ...

A next-generation, anti-CD19 enhanced CAR T-cell therapy that secretes interleukin-18 achieved a response in 81% of lymphoma patients who failed previous CAR T-cell therapy. Duration of response was 9 ...

Chimeric antigen receptor natural killer (CAR-NK) cell therapy is emerging as a promising next-generation immunotherapy with ...

CAR-T therapy is a major advance in cancer care, but high costs and centralized global manufacturing limit access.

Colleen Mabasa, a patient with multiple myeloma, discusses her CAR T-cell therapy journey and the pivotal role self-advocacy ...

Nona Biosciences inks agreement with Link Cell Therapies to advance CAR-T cell therapies: Cambridge, Massachusetts Monday, January 12, 2026, 11:00 Hrs [IST] Nona Biosciences (Nona ...